GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Return-on-Tangible-Equity

Catalent (Catalent) Return-on-Tangible-Equity : -98.30% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Catalent Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Catalent's annualized net income for the quarter that ended in Mar. 2024 was $-404 Mil. Catalent's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $411 Mil. Therefore, Catalent's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -98.30%.

The historical rank and industry rank for Catalent's Return-on-Tangible-Equity or its related term are showing as below:

CTLT' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -220.64   Med: 60.6   Max: 107.93
Current: -220.64

During the past 13 years, Catalent's highest Return-on-Tangible-Equity was 107.93%. The lowest was -220.64%. And the median was 60.60%.

CTLT's Return-on-Tangible-Equity is ranked worse than
93.71% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.475 vs CTLT: -220.64

Catalent Return-on-Tangible-Equity Historical Data

The historical data trend for Catalent's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Return-on-Tangible-Equity Chart

Catalent Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity 107.93 60.60 -39.35

Catalent Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.58 -69.84 -516.77 -163.49 -98.30

Competitive Comparison of Catalent's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalent's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Catalent's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Catalent's Return-on-Tangible-Equity falls into.



Catalent Return-on-Tangible-Equity Calculation

Catalent's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-256/( (709+592 )/ 2 )
=-256/650.5
=-39.35 %

Catalent's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-404/( (425+397)/ 2 )
=-404/411
=-98.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Catalent  (NYSE:CTLT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Catalent Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Catalent's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalent (Catalent) Business Description

Traded in Other Exchanges
Address
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Executives
David Mcerlane officer: Group President, Biologics C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven Barg director ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
Michelle R Ryan director 214 PARK BLVD S, VENICE FL 34285
John J Greisch director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Frank A Damelio director C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Aristippos Gennadios officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Thomas W Hawkeswood officer: Pres. Pharma Prod Delivery Div C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Patricia Hunt officer: Pres. Consumer Health Div C/O CATALENT, 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson officer: VP, Chief Accounting Officer CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lorenzo Carletti officer: SVP Global Ops Small Molecule C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricardo Pravda officer: SVP, Human Resources C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli officer: See remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Charles Lickfold officer: SVP, CIO C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther officer: See Remarks C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873

Catalent (Catalent) Headlines

From GuruFocus

Catalent Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Catalent Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Catalent Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Catalent Inc Investor Presentation Transcript

By GuruFocus Research 01-22-2024